Axsome Therapeutics (AXSM) News Today $68.59 +1.16 (+1.72%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$67.16▼$69.3150-Day Range$57.42▼$73.0652-Week Range$53.71▼$91.29Volume386,359 shsAverage Volume827,326 shsMarket Capitalization$3.25 billionP/E RatioN/ADividend YieldN/APrice Target$105.50 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAxsome Therapeutics, Inc. (NASDAQ:AXSM) Position Boosted by Bellevue Group AGmarketbeat.com - December 5 at 12:44 PMUPCOMING AXSM DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Axsome Therapeutics, Inc. Investors with Substantial Losses to Contact the Firm!barrons.com - December 3 at 12:41 PMAxsome Therapeutics: Positive Q3, We Like The Launch Success Storyseekingalpha.com - November 27 at 10:41 AMComparing BriaCell Therapeutics (OTCMKTS:BCTXF) & Axsome Therapeutics (NASDAQ:AXSM)americanbankingnews.com - November 25 at 2:28 AMAxsome Therapeutics to Host Solriamfetol Virtual Investor Event on December 7finance.yahoo.com - November 22 at 9:29 AMAxsome Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conferencefinance.yahoo.com - November 21 at 8:51 AMBuy Rating on Axsome Therapeutics: Financial Growth and Promising Pipeline despite Minor Setbacksmarkets.businessinsider.com - November 8 at 8:30 PMHold Rating on Axsome Therapeutics: Unchanged Strategies and Revenue Forecasts Amid Concerns on Future Sales and Profitability Trendsmarkets.businessinsider.com - November 7 at 1:40 PMAxsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimatesfinance.yahoo.com - November 7 at 1:40 PMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 7 at 8:40 AMQ3 2023 Axsome Therapeutics Inc Earnings Callfinance.yahoo.com - November 7 at 8:40 AMAxsome Therapeutics: Costs Outpacing Auvelity Growth (Rating Downgrade)seekingalpha.com - November 7 at 5:00 AMAnalysts Are Bullish on These Healthcare Stocks: Sangamo Biosciences (SGMO), Axsome Therapeutics (AXSM)markets.businessinsider.com - November 7 at 12:55 AMAxsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - November 6 at 9:48 AMAxsome Therapeutics Inc (AXSM) Reports 244% YoY Growth in 3Q 2023 Product Revenuefinance.yahoo.com - November 6 at 9:48 AMAxsome Therapeutics and the Global Alzheimer’s Disease Community Come Together in Raising Support for the Millions Affected by This Illness During Alzheimer’s Disease Awareness Month 2023finance.yahoo.com - November 2 at 8:19 AMAnalysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out forfinance.yahoo.com - October 30 at 2:20 PMAxsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conferencefinance.yahoo.com - October 24 at 10:33 AMBuy Rating Assigned to Axsome Therapeutics Amid Positive Prescription Trends for Auvelitymarkets.businessinsider.com - October 17 at 2:52 AMAxsome Update: Buy At Dips And Hold Foreverseekingalpha.com - October 16 at 6:11 AMAnalysts’ Top Healthcare Picks: Cytokinetics (CYTK), Axsome Therapeutics (AXSM)markets.businessinsider.com - October 12 at 10:28 AMAxsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directorsfinance.yahoo.com - October 11 at 8:13 AMAxsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6finance.yahoo.com - October 10 at 10:29 AMTruist Financial Keeps Their Buy Rating on Axsome Therapeutics (AXSM)markets.businessinsider.com - October 9 at 11:23 PMMizuho says market fears for Harmony's Wakix drug are "overblown"msn.com - October 4 at 2:27 PMMaintaining Buy Rating for Axsome Therapeutics: Steady Auvelity Sales and Anticipated Q3 Performance Insightsmarkets.businessinsider.com - October 3 at 8:45 AMAxsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Weekfinance.yahoo.com - October 2 at 10:10 AMAXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firmbusinesswire.com - September 28 at 11:00 PMAxsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Dayfinance.yahoo.com - September 21 at 9:32 AMMacquarie Group Ltd. Boosts Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - September 21 at 4:16 AMAxsome Therapeutics, Inc.'s (NASDAQ:AXSM) Earnings Haven't Escaped The Attention Of Investorsfinance.yahoo.com - September 19 at 8:01 AMInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells 11,016 Shares of Stockmarketbeat.com - September 15 at 8:28 PMBVF Inc. IL Buys 376,100 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - September 12 at 4:39 AMThis Promising Biotech Is Just Right for a Covered-Call Playrealmoney.thestreet.com - September 10 at 5:22 PMAxsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023finance.yahoo.com - September 7 at 9:29 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Boosted by WMS Partners LLCmarketbeat.com - September 5 at 1:53 PMAxsome Therapeutics to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - September 5 at 7:42 AMBank of New York Mellon Corp Has $7.72 Million Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - September 4 at 4:35 AMAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by Profund Advisors LLCmarketbeat.com - September 3 at 6:57 AMPearl River Capital LLC Buys 1,960 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - September 1 at 10:36 AMAxsome: Beyond The Numbers - Q2 Earnings Sparkle And A Pipeline Full Of Promiseseekingalpha.com - September 1 at 9:29 AM96,684 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Bought by ExodusPoint Capital Management LPmarketbeat.com - August 27 at 7:32 AMCantor Fitzgerald Reiterates Axsome Therapeutics (AXSM) Overweight Recommendationnasdaq.com - August 22 at 2:57 PMResources Investment Advisors LLC. Buys 1,621 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - August 22 at 6:49 AMAxsome Therapeutics (NASDAQ:AXSM) Now Covered by Analysts at StockNews.commarketbeat.com - August 17 at 2:56 AMBofA upgrades Axsome to neutral, cites improved outlook for MDD drugmsn.com - August 16 at 3:51 PMUS Bancorp DE Reduces Stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM)marketbeat.com - August 15 at 6:21 AMMizuho Maintains Axsome Therapeutics (AXSM) Buy Recommendationmsn.com - August 12 at 10:21 AMAxsome Therapeutics (NASDAQ:AXSM) PT Raised to $100.00 at Mizuhomarketbeat.com - August 11 at 8:00 AMFY2024 EPS Estimates for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Reduced by Cantor Fitzgeraldmarketbeat.com - August 10 at 9:33 AM Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.500.49▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼24▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARWR News RARE News CYTK News OGN News HCM News PBH News INSM News ZLAB News EVO News NUVL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:AXSM) was last updated on 12/5/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.